UroGen Pharma (URGN) Misses Q2 EPS by 22c

UroGen Pharma (NASDAQ: URGN) reported Q2 EPS of ($1.05), $0.22 worse than the analyst estimate of ($0.83). Revenue for the quarter came in at $24.2 million versus the consensus estimate of $23.13 million.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Candel Therapeutics Inc. (CADL) PT Raised to $15 at Freedom Broker
• Oppenheimer Downgrades AtaiBeckley Inc (ATAI) to Perform